Chemotherapy in Neuroendocrine/Merkel Cell Carcinoma of the Skin: Case Series and Review of 204 Cases
- 12 June 2000
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 18 (12) , 2493-2499
Abstract
PURPOSE: To study the use of chemotherapy for Merkel cell carcinoma (MCC) of the skin. PATIENTS AND METHODS: Twenty-five cases of MCC were treated at the London Regional Cancer Center between 1987 and 1997. Thirteen cases treated with chemotherapy were reviewed with 191 cases from the literature. RESULTS: At presentation, 24 patients had localized skin lesions (stage I) and one had locoregional involvement (stage II). Among the nine cases with recurrent nodal disease, six had chemotherapy as a component of salvage treatment. They were all free of disease at a median of 19 months (range, 12 to 37 months). In contrast, two patients who had salvage radiotherapy alone died of disease. Overall survival (OS) and disease-free survival (DFS) were 59% and 43%, respectively, at two years. Median OS and DFS were 29 months (range, 1 to 133 months) and 9 months (range, 1 to 133 months), respectively. Nodal disease developed in 12 (50%) of 24 patients with stage I disease, and distant metastases developed in six (25%) of 24. Including those from the literature, there were 204 cases treated with chemotherapy. Cyclophosphamide/doxorubicin (or epirubicin)/vincristine combination ± prednisone was the most commonly used chemotherapy regimen (47 cases), with an overall response rate of 75.7% (35.1% complete, 35.1% partial, and 5.4% minor responses). Etoposide/cisplatin (or carboplatin) was the next most commonly used regimen (27 cases), with an overall response rate of 60% (36% complete and 24% partial responses). The difference in response rate was not statistically significant (P = .19). Among the 204 cases, there were seven (3.4%) toxic deaths. CONCLUSION: Chemoradiation for locally recurrent or advanced disease may be an option for patients with a good performance status.Keywords
This publication has 65 references indexed in Scilit:
- Merkel cell carcinoma: Report of ten cases with emphasis on clinical course, treatment, and in vitro drug sensitivityJournal of the American Academy of Dermatology, 1997
- Merkel cell carcinoma of the scalp: Dramatic resolution with primary chemotherapyJournal of the American Academy of Dermatology, 1994
- Merkel cell carcinomaJournal of the American Academy of Dermatology, 1993
- PRIMARY MERKEL CELL TUMOR: A CLINICAL ANALYSIS OF EIGHT CASESInternational Journal of Dermatology, 1993
- Response of metastatic adenoid cystic carcinoma and Merkel cell tumor to high-dose Melphalan with autologous bone marrow transplantationInvestigational New Drugs, 1992
- Le carcinome neuroendocrine cutané A propos d'une observationLa Revue de Médecine Interne, 1990
- Merkel cell (small cell) carcinoma of the skin: Immunohistochemical and ultrastructural demonstration of distinctive perinuclear cytokeratin aggregates and a possible association with B cell neoplasmsJournal of Molecular Histology, 1986
- Serum neuron‐specific enolase in metastatic merkel cell tumorsMedical and Pediatric Oncology, 1985
- Primary neuroendocrine carcinoma of the skin (Merke's cell carcinoma)Journal of Surgical Oncology, 1984
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958